These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 10479408)
1. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; de Man BM; van der Meer JW; Goris RJ Cytokine; 1999 Sep; 11(9):713-21. PubMed ID: 10479408 [TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Hermsen R; Van der Meer JW; Goris RJ Cytokine; 1998 Nov; 10(11):904-10. PubMed ID: 9878128 [TBL] [Abstract][Full Text] [Related]
3. Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Malleo G; Mazzon E; Genovese T; Di Paola R; Caminiti R; Esposito E; Bramanti P; Cuzzocrea S Cytokine; 2008 Feb; 41(2):136-43. PubMed ID: 18160304 [TBL] [Abstract][Full Text] [Related]
4. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. Jansen MJ; Hendriks T; Knapen MF; van Kempen LC; van der Meer JW; Goris RJ Crit Care Med; 1998 Jul; 26(7):1244-50. PubMed ID: 9671376 [TBL] [Abstract][Full Text] [Related]
5. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436 [TBL] [Abstract][Full Text] [Related]
6. Treatment with Y-40138, a multiple cytokine production modulator, inhibits lipopolysaccharide- or tumour necrosis factor-alpha-induced production of pro-inflammatory cytokines and augments interleukin-10. Fukuda T; Hisadome M; Komatsu H J Pharm Pharmacol; 2005 Nov; 57(11):1461-6. PubMed ID: 16259779 [TBL] [Abstract][Full Text] [Related]
7. Role of interleukin-6 in a non-septic shock model induced by zymosan. Cuzzocrea S; de Sarro G; Costantino G; Mazzon E; Laurà R; Ciriaco E; de Sarro A; Caputi AP Eur Cytokine Netw; 1999 Jun; 10(2):191-203. PubMed ID: 10400825 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Netea MG; Kullberg BJ; Verschueren I; Van Der Meer JW Eur J Immunol; 2000 Oct; 30(10):3057-60. PubMed ID: 11069090 [TBL] [Abstract][Full Text] [Related]
10. The immunomodulatory effects of the herbicide propanil on murine macrophage interleukin-6 and tumor necrosis factor-alpha production. Xie YC; Schafer R; Barnett JB Toxicol Appl Pharmacol; 1997 Jul; 145(1):184-91. PubMed ID: 9221836 [TBL] [Abstract][Full Text] [Related]
11. Peritoneal mesothelial cells produce inflammatory related cytokines. Yao V; Platell C; Hall JC ANZ J Surg; 2004 Nov; 74(11):997-1002. PubMed ID: 15550091 [TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Jansen MJ; Hendriks T; Vogels MT; van der Meer JW; Goris RJ Crit Care Med; 1996 Jul; 24(7):1196-202. PubMed ID: 8674335 [TBL] [Abstract][Full Text] [Related]
13. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shayevitz JR; Miller C; Johnson KJ; Rodriguez JL Shock; 1995 Dec; 4(6):389-96. PubMed ID: 8608394 [TBL] [Abstract][Full Text] [Related]
14. Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan. Di Paola R; Esposito E; Mazzon E; Genovese T; Muià C; Crisafulli C; Malleo G; Sessa E; Meli R; Cuzzocrea S Shock; 2006 Nov; 26(5):477-84. PubMed ID: 17047518 [TBL] [Abstract][Full Text] [Related]
16. Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice. Mondello S; Galuppo M; Mazzon E; Italiano D; Mondello P; Aloisi C; Cuzzocrea S Eur J Pharmacol; 2011 May; 658(1):28-40. PubMed ID: 21349270 [TBL] [Abstract][Full Text] [Related]
17. Dose-dependent improvements in outcome with adenoviral expression of interleukin-10 in a murine model of multisystem organ failure. McAuliffe PF; Murday ME; Efron PA; Scumpia PO; Ungaro R; Abouhamze A; Tannahill CL; Hutchins B; LaFace D; Moldawer LL Gene Ther; 2006 Feb; 13(3):276-82. PubMed ID: 16251998 [TBL] [Abstract][Full Text] [Related]
18. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Volman TJ; Hendriks T; Verhofstad AA; Kullberg BJ; Goris RJ Shock; 2002 Jun; 17(6):468-72. PubMed ID: 12069182 [TBL] [Abstract][Full Text] [Related]
19. GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan. Galuppo M; Nocentini G; Mazzon E; Ronchetti S; Esposito E; Riccardi L; Di Paola R; Bruscoli S; Riccardi C; Cuzzocrea S Shock; 2011 Sep; 36(3):263-71. PubMed ID: 21654556 [TBL] [Abstract][Full Text] [Related]
20. Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome. Volman TJ; Goris RJ; Lomme RM; DeGroot J; Verhofstad AA; Hendriks T J Pathol; 2004 Aug; 203(4):968-75. PubMed ID: 15259001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]